Background-Polymer-coated drug-eluting stents are effective in preventing restenosis but have been associated with delayed healing and incomplete strut coverage. It is unknown whether paclitaxel-eluting stents (PES) with minimal biodegradable abluminal coating enhances strut coverage while preventing neointimal hyperplasia. Using optical coherence tomography (OCT) as a primary imaging modality, we assessed the proportion of uncovered struts at 6-month follow-up in PES coated with durable versus ultrathin (Ͻ1 m) biodegradable abluminal polymers. Methods and Results-In this pilot trial, 60 patients with de novo lesions (Յ25 mm) in native coronary vessels were randomly assigned to receive either TAXUS Liberté PES or JACTAX PES, a Liberté stent with polymer deposited abluminally as microdots (JACTAX HD: 9.2 g each of polymer and paclitaxel per 16-mm stent; JACTAX LD: 5 g each). OCT follow-up occurred at 6 months with clinical follow-up through 1 year. The primary end point was percent uncovered struts by OCT. An independent core laboratory blinded to stent assignment analyzed images. The 6-month rate of uncovered struts per patient was 5.3Ϯ14.7% for TAXUS Liberté, 7.0Ϯ12.2% for JACTAX HD, and 4.6Ϯ7.3% for JACTAX LD (Pϭ0.81); percent malapposed struts was 1.4Ϯ4.4%, 0.8Ϯ1.9%, and 1.1Ϯ2.8%, respectively (Pϭ0.86). Strut-level intimal thickness was 0.20Ϯ0.10, 0.22Ϯ0.15, and 0.24Ϯ0.15 mm (Pϭ0.64); percent volume obstruction by OCT was 22.2Ϯ12.8, 22.5Ϯ16.2, and 25.8Ϯ15.2 (Pϭ0.69). There were no deaths, Q-wave myocardial infarctions, or stent thromboses through 1 year.
D rug-eluting stents (DES) have been shown to reduce restenosis compared with bare metal stents 1-2 without significantly increasing short-or long-term rates of death or myocardial infarction (MI). 3 However, current DES that deliver drugs through a durable polymer delivery system have been associated with an increased risk of late and very late stent thrombosis (ST), 4 attributed to delayed arterial healing with incomplete reendothelialization and/or a chronic inflammatory response as suggested by preclinical, autopsy, and clinical studies. 5, 6 DES with abluminally applied biodegradable polymers that leave a polymer-free bare metal stents after drug release are being tested to minimize the thrombotic risk. [7] [8] [9] [10] The novel JACTAX paclitaxel-eluting stent (PES) contains minimal amounts of biodegradable polylactide polymer plus drug applied to the abluminal surface as discrete microdots, which deliver paclitaxel directly to the coronary vessel wall over approximately 90 days while excluding polymer and drug from contact with the vessel lumen. 11 The ultrathin coating (Յ1 m, Figure 1 ) is designed to resorb in approximately 6 months, thereby eliminating chronic exposure to drug and polymer. It is unknown whether DES with a minimal amount of biodegradable abluminal coating can enhance strut coverage while maintaining efficacy in prevention of neointimal hyperplasia.
Clinical Perspective on p 375
Optical coherence tomography (OCT) is a high-resolution (Ϸ10 to 20 m axial) imaging technique that allows a more precise assessment of strut coverage and stent apposition than either angiography or intravascular ultrasound (IVUS). 12 The Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI) is a randomized controlled trial designed to evaluate completeness of strut coverage and vessel wall response at 6 months after implantation of the JACTAX stent versus the durable polymer TAXUS Liberté PES using OCT as the primary imaging modality.
Methods

Study Design
In this prospective, single-center pilot trial, 60 patients were randomly assigned equally to receive either JACTAX HD (high dose, 9.2 g each of polymer and paclitaxel per 16-mm stent), JACTAX LD (low dose, 5.0 g each), or TAXUS Liberté (all stents from Boston Scientific Corporation, Natick, Mass). Randomization was stratified by lesion length (Յ15 mm versus Ͼ15 mm) to ensure a more even distribution of stent length across groups. The study was conducted under Good Clinical Practice conditions and in compliance with the Medical Device Regulations for Italy. The Ethics Review Committee of Ospedali Riuniti di Bergamo approved the protocol; patients provided written informed consent before enrollment. The investigators, sponsor, core laboratories, and contract research organization managing the study are listed in supplemental Table 1 .
Patient Selection, Procedure, and Follow-Up
Eligible patients (age, Ն18 years) had a de novo lesion in a native coronary artery with lesion length Յ25 mm, diameter stenosis (DS) Ն70%, and reference vessel diameter (RVD) 2.75 to 3.5 mm by visual estimation. Key exclusion criteria included moderate/severe target lesion calcification, bifurcation with a Ͼ50% stenotic branch vessel Ͼ2.0 mm in diameter, acute MI, stroke or transient ischemic attack Ͻ3 months before the procedure, and allergy or contraindication to aspirin, clopidogrel, ticlopidine, paclitaxel, or stainless steel. Excessive target lesion tortuosity and ostial location were also exclusion criteria because these factors could interfere with OCT image acquisition. A nonstudy lesion in a different epicardial vessel could be stented if successfully implanted without complication before patient enrollment. Intracoronary nitroglycerin (200 g) was administered before imaging procedures. Aspirin (100 mg daily) was mandated per protocol for 12 months and recommended indefinitely. All patients received clopidogrel (75 mg) daily for a minimum of 6 months, recommended for 12 months. Angiographic, OCT, and IVUS follow-up occurred at 6 months.
Quantitative Coronary Angiography
Quantitative coronary angiography was done at baseline, immediately after percutaneous coronary intervention, and at follow-up. Digital coronary angiograms were analyzed offline by an independent core laboratory (Beth Israel Deaconess) using validated quantitative methods. 13
Intravascular Ultrasound
IVUS imaging was performed at 6-month follow-up using the Atlantis SR Pro 40 MHz catheter and the iLab ultrasound console (Boston Scientific, Natick, Mass). Using a motorized pullback at 1 mm/s, images were continuously recorded throughout the stent and at least 5 mm distal and proximal to the stent. All IVUS data were digitally stored for subsequent analysis. Quantitative volumetric IVUS analysis was performed using a validated semiautomated detection algorithm (Curad, version 4.32, Wijk Bij Duurstede, The Netherlands) and previously described methodology. 14 
OCT Imaging Acquisition and Analyses
OCT images were obtained at 6-month follow-up. A time-domain OCT system (M2CV OCT Imaging System, LightLab Imaging, Westford, Mass) was used, and an occlusive technique was adopted to completely remove blood from the artery. 15 Images were acquired with an automated pullback at a rate of 1.0 mm/s, then digitally stored and submitted to the core laboratory for offline analysis. All cross-sectional images (frames) were initially screened for quality assessment. Frames were excluded from analysis if any portion of the vessel was out of the screen, if a side branch occupied Ͼ45°of the cross section or if the image had poor quality caused by residual blood, sew-up artifact, or reverberation. 16 A dedicated semiautomated contour-detection system (OCT system software B.0.1, LightLab), developed in collaboration with the University Hospital's Imaging Core Laboratory, was used for measurements. Lumen, stent, and neointimal hyperplasia areas and volumes were determined at 0.6-mm intervals. Quantitative strut level analysis was performed at every frame (0.06-mm interval) along the entire target segment. A strut was considered suitable for analysis only if it had a well defined bright "blooming" appearance and a characteristic shadow perpendicular to the light source. The center of the luminal surface of the strut blooming was determined for each strut and its distance to the lumen contour was calculated automatically to determine strut-level intimal thickness (SIT). Struts covered by tissue had positive SIT values, whereas uncovered or malapposed struts had negative SIT. Strut malapposition was defined when the negative value of SIT was higher than the sum of strut thickness plus abluminal polymer thickness according to each stent manufacturer specifications plus a compensation factor of 20 m to correct for strut blooming. This blooming compensation factor was selected based on an analysis of 2250 struts. 17 The final cutoff value for malapposition was 136 m for TAXUS Liberté and 118 m for JACTAX. Qualitative imaging assessment was also performed to detect the presence of abnormal intraluminal tissue (AIT), defined as any irregular mass protruding beyond the stent strut into the lumen, and further classified as related to uncovered or malapposed struts. Although OCT can accurately identify acute thrombus, 18 it is more difficult to distinguish chronic thrombus with fibrin from underlying neointima. 19 Thus, we adopted the more descriptive term AIT to describe intraluminal protruding masses. Highly reproducible measurements for strut apposition and strut coverage using the described methodology have been reported. 20 Validation and reproducibility measurements at the core laboratory were performed on 333 struts measured by 2 independent analysts and repeated 3 months later. The absolute difference between 2 analysts in SIT was 0.01Ϯ0.02 m (Rϭ0.997). Interobserver and intraobserver variability showed substantial agreement for AIT qualitative assessment (ϭ0.755 and 0.885, respectively). Figure 2 shows OCT images from a representative JACTAX stent with multiple frames analyzed at different locations within the stent.
End Points and Data Management
The primary end point was the percentage of uncovered stent struts at 6-month follow-up as measured by OCT. Secondary OCT end points included the rate of malapposed struts and the percent of OCT cross sections where Ͼ30% of struts were uncovered. Imaging end points were all analyzed by independent core laboratories (supplemental Table 1 ). Clinical outcomes (defined in supplemental Table  2 ) included major adverse cardiac events (MACE, a composite of cardiac death, MI, and target vessel revascularization), target lesion revascularization, and ST per the Academic Research Consortium definitions of definite/probable 21 and were to be evaluated at discharge, 1, and 6 months (by hospital visit) and 12 and 24 months (by phone call). Lesion success was defined as successful stent deployment with TIMI flow Ն2 and in-stent %DS Յ30% (by core laboratory quantitative coronary angiography). Procedural success included lesion success without MACE through discharge. Independent adjudication was performed for MACE and ST and an auton-omous data monitoring committee reviewed safety data on a regular basis (Supplemental Table 1 ).
Statistical Methods
The analysis sample for the primary end point was the intent-to-treat population. Patient, lesion, and procedural characteristics and event rates were analyzed using descriptive statistics with SAS version 9.1 or higher (SAS Institute Inc, Cary, NC). Categorical data are reported as simple proportions; continuous data are reported as meanϮstandard deviation. Tests for the overall comparison across the 3 groups included ANOVA for continuous variables and Fisher exact test for categorical variables; PϽ0.05 was considered significant.
Results
Patient, Lesion, and Procedural Characteristics
Baseline clinical and procedural characteristics are shown in Table 1 . The 3 cohorts (TAXUS Liberté, nϭ19; JACTAX LD, nϭ21; JACTAX HD, nϭ20) were not significantly different from each other except with respect to the occurrence of previous percutaneous coronary intervention (Pϭ0.04). Lesion success was 100% in all 3 cohorts. Procedural success was 100% for TAXUS Liberté and JACTAX LD and 98.3% (20/21) for JACTAX HD (non-Q-wave MI). The rate of follow-up with angiography, IVUS, and OCT at 6 months was 100%.
Quantitative Coronary Angiography
Angiographic assessments before the procedure, after the procedure, and at 6 months are shown in Table 2 . At baseline, the 3 cohorts were similar to each other except that lesion 
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%DS was higher (Pϭ0.006) and minimum lumen diameter was lower (Pϭ0.019) in patients treated with JACTAX LD. Nevertheless, postprocedure minimum lumen diameter and residual stenosis were similar for all groups (Pϭ0.53 in-stent, Pϭ0.25 in-segment). At 6 months, in-stent late loss was 0.39 mm for JACTAX LD, 0.25 mm for JACTAX HD, and 0.24 mm for TAXUS Liberté (Pϭ0.39). In-stent binary restenosis was 4.8% for JACTAX LD, 0.0% for JACTAX HD, and 5.3% for TAXUS Liberté (Pϭ0.76).
Optical Coherence Tomography
Of 24 101 total frames collected by OCT, 73.4% 17 698 were analyzed. Frames were excluded from analysis either because of bifurcation location (3967; 16.5%) or any image artifact (2436, 10.1%, see Methods). Table 3 shows OCT results at 6 months. There were no significant differences among the treatment groups. The percent of uncovered struts per patient ranged from 4.6% to 7.0% in the 3 groups (Table 3 ). Whereas the majority of patients had at least 1 uncovered strut (range, 79.0% to 85.0%), most patients had Ͼ95% strut coverage (Figure 3 ). The percent of malapposed struts per patient ranged from 0.8% to 1.4%. The frequency distribution of SIT was also similar across the 3 cohorts ( Figure 4 ). Seven patients had AIT; 6 cases were related to malapposed struts and only 1 to uncovered struts (Table 3) .
Intravascular Ultrasound and Clinical Outcomes
IVUS results are shown in Table 4 . IVUS outcomes were similar across the 3 groups. Follow-up through 1 year was 98.3% (59/60). There were no episodes of death, Q-wave MI, or stent thrombosis. Total MACE was 6.8% (4/59) and included 2 non-Q-wave MI (JACTAX HD and TAXUS) and 2 target lesion revascularization (JACTAX LD).
Discussion
This pilot study showed that the use of the JACTAX PES with an ultrathin, abluminal microdot biodegradable polymer coating did not result in improved strut coverage at 6 months compared with TAXUS Liberté with a conformal and durable polymer. By OCT, all 3 PES platforms had Ͼ93% of struts covered and apposed to the vessel wall at 6 months and similar strut level intimal thickness (approximately 0.2 mm). These OCT data support the antirestenotic efficacy and clinical feasibility of JACTAX with 10-fold less drug and polymer load as reported in the First-Human-Use trial 11 but do not suggest an advantage in terms of strut coverage at 6 months.
First-generation DES were designed to prevent restenosis but have been associated with increased rates of late ST. 4 Poor stent endothelialization, inflammatory reaction to the durable polymer coating, and delayed healing have been proposed as potential causes of late thrombotic events. 5 This contrasts with bare metal stents, in which patients have low ST rates and nearly complete endothelialization. Drug and polymer toxicity along with incomplete strut coverage have been implicated in pathological DES vascular responses. 6 Abluminally applied biodegradable polymers can limit vascular exposure, providing a polymer-free microenvironment to minimize potential inflammatory responses, but these approaches may lead to subtherapeutic dose levels and clinical failure to prevent restenosis. 10 This study is, to the best of our knowledge, one of the first assessing a novel DES with an OCT primary end point. In the current study, strut coverage at 6 months was Ͼ93% in all 3 cohorts, which compares favorably to previous reports with first generation DES. 17, 22 In the Leaders trial, the biodegradable polymer-coated biolimus-eluting stent showed more complete coverage than sirolimus-eluting stents by OCT at 9 months. 23 However, JACTAX showed no apparent benefit to paclitaxel delivery via a biodegradable abluminal polymer in terms of improved strut coverage at 6 months. A possible explanation for these findings may be that the 6-month OCT time point was too early relative to complete polymer absorption. A significant decrease in the frequency of uncovered sirolimus-eluting stent struts (from 10.4% to 5.7%, PϽ0.0001) with no shift in neointimal thickness distribution has been reported between 6 and 12 months. 24 It remains to be determined if subsequent (Ն1 year) OCT imaging will reveal differences in coverage between JACTAX and durable polymer stents.
Because ST risk increases with the ratio of uncovered to total stent struts, 25 we measured the frequency of analyzed frames with Ն30% uncovered stent struts and found no differences between the 3 cohorts. Stent malapposition, and the resulting incomplete neointimal coverage of malapposed struts, has also been identified as a predisposing factor for late ST. 26 In the present study, postprocedure malapposition was significantly more common in the TAXUS Liberté group than in either of the JACTAX arms by IVUS. The high rate of postprocedure malapposition with TAXUS Liberté in OCTDESI may be a chance finding in this relatively small exploratory study because it is higher than has been previously reported in larger IVUS studies of TAXUS Liberté. 27 In OCTDESI, all 3 groups showed a low 6-month rate of malapposed struts per patient (approximately 1%), a rela- Numbers are n (%) or meanϮSD. Cx indicates circumflex; LAD, left anterior descending artery; MLD, minimum lumen diameter; RCA, right coronary artery; and RVD, reference vessel diameter.
*Test for overall comparison across the 3 treatment groups: ANOVA for continuous variables, exact 2 test for categorical variables.
†In-segment analysis included the segment covered by the stent (in-stent) plus 5-mm segments proximal and distal to the stent edge. ‡Binary restenosis (Ն50% DS).
tively short malapposition distance (0.07 to 0.11 mm) and length of malapposed segment (Ͻ0.5 mm) by OCT, and no late-acquired malapposition by IVUS. These findings are consistent with the low rate of 1-year adverse events observed in this trial, and in the JACTAX arms may be a consequence of low total amount of paclitaxel loaded on the stent. One patient (1.7%) displayed AIT related to uncovered struts, whereas 6 patients (10.0%) had AIT related to malapposed struts. Interestingly, AIT was more commonly associated with malapposed stent struts than with fully apposed but uncovered struts. The rate of AIT detected by OCT in the present study compares favorably to the relatively high frequency of subclinical thrombi reported by others 28 with sirolimus-eluting stents, but these differences might be related to the more stringent approach used for identification of intraluminal protruding masses or to differences in study populations.
OCT can provide a high level of accuracy in evaluating minimal amounts of coverage and heterogeneity of vascular †Strut level analysis was conducted every frame except for measurements of intimal thickness and percent of frames with Ͼ30% uncovered struts, which were quantified at intervals of every 10 frames; morphometric analysis was performed at intervals of every 10 frames; numbers are meanϮSD. response after DES implantation, beyond what can be ascertained with angiography and IVUS. 12, 22 In the present study, OCT detected a higher level of net volume obstruction than IVUS that was probably caused by its higher resolution and sensitivity in assessing low levels of intimal thickness. OCT, IVUS, and angiography together provided a sensitive measure of strut level neointimal thickness at 6 months and showed that the JACTAX HD stent was as effective as the conventional TAXUS Liberté stent in suppressing neointimal proliferation. In-stent late loss and %DS as assessed by angiography and percent net volume obstruction by OCT and IVUS were numerically higher with JACTAX LD compared with JACTAX HD and TAXUS Liberté (Tables 2, 3, and 4), suggesting that 5 g per 16-mm stent may reflect the lower limit of efficacy with paclitaxel. However, because these differences were not statistically significant, it is also possible that the differences are due to chance; further studies are required to confirm these findings. It is notable that JACTAX HD and TAXUS Liberté had similar antirestenotic effects (as measured by in-stent late loss) despite having different release kinetics and total paclitaxel content. With JACTAX (both LD and HD), the majority of the paclitaxel loaded on the stent is released within the first 10 days after implantation, whereas only 10% of the drug load is released in the first 10 days with TAXUS. The total amount of paclitaxel released by JACTAX HD and TAXUS Liberté over the first 10 days is comparable, however, and this may explain the similar efficacy profile.
The PISCES trial tested several PES formulations with 5 to 10 g of paclitaxel and release duration Յ10 days using a biodegradable polymer and laser cut holes in the stent. 8 High in-stent late loss was observed at 4 months (0.67 to 0.72 mm). Differences in the techniques used to quantify paclitaxel release, subtle differences in release profile, or other unidentified factors may explain differences between the results observed in the present study and PISCES. Overall, the OCTDESI results support the concept that drug dosage and polymer load can be reduced without jeopardizing the antirestenotic properties of DES but without improvement in 6-month strut coverage.
Study Limitations
The present study includes a small number of patients with relatively simple lesions. Moreover, the study was not powered or designed to investigate the clinical implications of OCT end points. Future evaluations linking clinical outcomes to OCT end points are needed. In addition, current OCT systems cannot detect Ͻ15 m tissue coverage and cannot differentiate very small amounts of fibrin deposition or inflammatory cellular response from underlying neointimal hyperplasia. Future developments in OCT technology are necessary to allow tissue characterization.
Conclusion
The results of the pilot OCTDESI trial showed that the novel JACTAX stent with an ultrathin abluminal coating of discrete microdots of paclitaxel in a biodegradable polymer did not result in improved strut coverage but did provide strut coverage and neointimal inhibition similar to that achieved with a conventional conformal durable polymer TAXUS Liberté stent. Late acquired 0 (0.0%) 0 (0.0%) 0 (0.0%) . . .
Numbers are meanϮSD or n (%). *Test for overall comparison across the 3 treatment groups: ANOVA for continuous variables, exact 2 test for categorical variables.
†Categorized as resolved (visible only at postprocedure), persistent (visible at postprocedure and follow-up), or late acquired (visible only at follow-up).
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